Viviany Rodrigues Taqueti, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fractional Flow Reserve, Myocardial | 19 | 2022 | 290 | 5.120 |
Why?
|
Coronary Artery Disease | 41 | 2024 | 6487 | 4.160 |
Why?
|
Myocardial Perfusion Imaging | 18 | 2023 | 554 | 2.970 |
Why?
|
Coronary Circulation | 21 | 2023 | 1572 | 2.650 |
Why?
|
Myocardial Ischemia | 13 | 2023 | 2148 | 2.240 |
Why?
|
Microcirculation | 9 | 2023 | 1286 | 1.830 |
Why?
|
Positron-Emission Tomography | 31 | 2023 | 6234 | 1.740 |
Why?
|
Coronary Vessels | 11 | 2023 | 3107 | 1.510 |
Why?
|
Microvascular Angina | 2 | 2020 | 15 | 1.190 |
Why?
|
Coronary Angiography | 17 | 2023 | 4577 | 1.160 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 7 | 2023 | 1107 | 1.010 |
Why?
|
Cardiology | 5 | 2023 | 1668 | 0.920 |
Why?
|
Angina Pectoris | 5 | 2023 | 977 | 0.910 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 127 | 0.900 |
Why?
|
Microvessels | 4 | 2015 | 544 | 0.870 |
Why?
|
Myocarditis | 4 | 2021 | 771 | 0.850 |
Why?
|
Heart | 10 | 2024 | 4467 | 0.720 |
Why?
|
Angina Pectoris, Variant | 1 | 2019 | 55 | 0.720 |
Why?
|
Plaque, Atherosclerotic | 3 | 2022 | 1519 | 0.680 |
Why?
|
Coronary Vasospasm | 1 | 2019 | 88 | 0.680 |
Why?
|
Cardiovascular Diseases | 10 | 2023 | 15165 | 0.660 |
Why?
|
Exercise Test | 7 | 2021 | 2074 | 0.610 |
Why?
|
Heart Failure, Diastolic | 1 | 2018 | 69 | 0.590 |
Why?
|
Heart Failure | 8 | 2023 | 10900 | 0.570 |
Why?
|
Manikins | 2 | 2008 | 238 | 0.510 |
Why?
|
Coronary Stenosis | 2 | 2018 | 834 | 0.500 |
Why?
|
Troponin | 2 | 2018 | 524 | 0.500 |
Why?
|
Heart Diseases | 2 | 2024 | 2788 | 0.470 |
Why?
|
Cardiomyopathies | 6 | 2022 | 1912 | 0.440 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 3670 | 0.430 |
Why?
|
Stroke Volume | 8 | 2023 | 5007 | 0.430 |
Why?
|
Chest Pain | 2 | 2017 | 1114 | 0.420 |
Why?
|
Ticlopidine | 1 | 2017 | 899 | 0.390 |
Why?
|
Humans | 90 | 2024 | 744343 | 0.390 |
Why?
|
Drug-Eluting Stents | 2 | 2018 | 753 | 0.390 |
Why?
|
Defibrillators, Implantable | 2 | 2018 | 1440 | 0.390 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2017 | 531 | 0.390 |
Why?
|
Myocardial Infarction | 7 | 2020 | 11727 | 0.390 |
Why?
|
Regional Blood Flow | 1 | 2014 | 1525 | 0.380 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2022 | 1240 | 0.380 |
Why?
|
Molecular Imaging | 2 | 2021 | 828 | 0.380 |
Why?
|
Capillary Permeability | 1 | 2014 | 798 | 0.380 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3255 | 0.370 |
Why?
|
Cardiac Imaging Techniques | 3 | 2018 | 269 | 0.370 |
Why?
|
Prognosis | 14 | 2022 | 29063 | 0.360 |
Why?
|
Carotid Arteries | 1 | 2014 | 952 | 0.350 |
Why?
|
Inflammation | 5 | 2021 | 10638 | 0.350 |
Why?
|
Predictive Value of Tests | 13 | 2023 | 15076 | 0.340 |
Why?
|
Carotid Stenosis | 2 | 2014 | 854 | 0.340 |
Why?
|
Image Enhancement | 2 | 2016 | 2921 | 0.320 |
Why?
|
Ventricular Remodeling | 3 | 2022 | 1224 | 0.320 |
Why?
|
Teaching Materials | 1 | 2008 | 86 | 0.320 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3507 | 0.320 |
Why?
|
Sarcoidosis | 3 | 2019 | 506 | 0.320 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1836 | 0.300 |
Why?
|
Coronary Artery Bypass | 2 | 2014 | 2289 | 0.300 |
Why?
|
Clinical Medicine | 1 | 2008 | 147 | 0.290 |
Why?
|
Blood Vessels | 1 | 2013 | 1125 | 0.290 |
Why?
|
Women's Health | 1 | 2016 | 2034 | 0.290 |
Why?
|
Heroin Dependence | 1 | 2007 | 175 | 0.280 |
Why?
|
Health Status Disparities | 1 | 2018 | 1797 | 0.270 |
Why?
|
Obesity | 4 | 2024 | 12745 | 0.260 |
Why?
|
Female | 47 | 2023 | 380194 | 0.260 |
Why?
|
Rubidium Radioisotopes | 2 | 2017 | 85 | 0.260 |
Why?
|
Radiopharmaceuticals | 7 | 2021 | 2645 | 0.260 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2019 | 2016 | 0.260 |
Why?
|
Education, Medical | 2 | 2008 | 1721 | 0.250 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2017 | 3068 | 0.240 |
Why?
|
Technetium Tc 99m Pyrophosphate | 2 | 2020 | 44 | 0.240 |
Why?
|
T-Box Domain Proteins | 1 | 2006 | 471 | 0.240 |
Why?
|
Treatment Refusal | 1 | 2007 | 421 | 0.240 |
Why?
|
Coronary Disease | 4 | 2023 | 6077 | 0.240 |
Why?
|
Myocardial Bridging | 1 | 2023 | 11 | 0.240 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2635 | 0.240 |
Why?
|
Male | 41 | 2023 | 350118 | 0.230 |
Why?
|
Heart Transplantation | 4 | 2021 | 3110 | 0.230 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 669 | 0.230 |
Why?
|
Coronary Restenosis | 2 | 2018 | 424 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2017 | 9959 | 0.220 |
Why?
|
Risk Factors | 16 | 2023 | 72290 | 0.220 |
Why?
|
Cadmium | 2 | 2022 | 212 | 0.220 |
Why?
|
Acute Coronary Syndrome | 1 | 2016 | 2337 | 0.220 |
Why?
|
Peer Review, Research | 2 | 2023 | 329 | 0.210 |
Why?
|
Aged | 28 | 2022 | 163280 | 0.200 |
Why?
|
Myocardial Revascularization | 2 | 2016 | 841 | 0.200 |
Why?
|
Middle Aged | 28 | 2023 | 213383 | 0.190 |
Why?
|
Tellurium | 1 | 2020 | 23 | 0.190 |
Why?
|
Nuclear Medicine | 1 | 2023 | 233 | 0.190 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 11725 | 0.180 |
Why?
|
Zinc | 2 | 2022 | 684 | 0.180 |
Why?
|
Death, Sudden, Cardiac | 3 | 2018 | 1541 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 6 | 2022 | 20129 | 0.170 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2006 | 1821 | 0.170 |
Why?
|
Thrombosis | 1 | 2013 | 2968 | 0.170 |
Why?
|
Thoracic Neoplasms | 1 | 2020 | 268 | 0.160 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 1965 | 0.160 |
Why?
|
American Heart Association | 4 | 2023 | 1056 | 0.150 |
Why?
|
Technetium | 1 | 2017 | 334 | 0.150 |
Why?
|
Atherosclerosis | 1 | 2013 | 3445 | 0.140 |
Why?
|
Review Literature as Topic | 1 | 2018 | 336 | 0.140 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2017 | 153 | 0.140 |
Why?
|
Vasodilator Agents | 2 | 2021 | 977 | 0.140 |
Why?
|
Cardiovascular System | 1 | 2023 | 832 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 35421 | 0.130 |
Why?
|
Medicine | 1 | 2023 | 946 | 0.130 |
Why?
|
Reproducibility of Results | 6 | 2022 | 19905 | 0.120 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2019 | 2208 | 0.120 |
Why?
|
Cell Movement | 1 | 2006 | 5217 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1161 | 0.120 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39050 | 0.120 |
Why?
|
Electric Countershock | 1 | 2017 | 534 | 0.120 |
Why?
|
Amyloidosis | 1 | 2020 | 795 | 0.120 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2016 | 262 | 0.110 |
Why?
|
Vascular Resistance | 1 | 2016 | 936 | 0.110 |
Why?
|
Treatment Outcome | 7 | 2020 | 63114 | 0.110 |
Why?
|
Troponin I | 1 | 2017 | 619 | 0.110 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2023 | 285 | 0.110 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2020 | 2073 | 0.100 |
Why?
|
Psoriasis | 1 | 2020 | 898 | 0.100 |
Why?
|
Troponin T | 1 | 2017 | 754 | 0.100 |
Why?
|
Ammonia | 2 | 2022 | 239 | 0.100 |
Why?
|
Risk Assessment | 5 | 2022 | 23338 | 0.100 |
Why?
|
Hypertension | 2 | 2022 | 8480 | 0.100 |
Why?
|
Health Personnel | 1 | 2004 | 3218 | 0.100 |
Why?
|
Radiation Dosage | 1 | 2019 | 1928 | 0.090 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 850 | 0.090 |
Why?
|
Retrospective Studies | 14 | 2022 | 77449 | 0.090 |
Why?
|
Fasting | 1 | 2016 | 1593 | 0.090 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2014 | 1475 | 0.090 |
Why?
|
Severity of Illness Index | 4 | 2017 | 15540 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2019 | 14722 | 0.080 |
Why?
|
Prevalence | 2 | 2023 | 15226 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6895 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2019 | 57776 | 0.080 |
Why?
|
Career Choice | 1 | 2014 | 744 | 0.080 |
Why?
|
Sex Factors | 2 | 2020 | 10397 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1790 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6489 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12245 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2015 | 1786 | 0.070 |
Why?
|
Lipids | 1 | 2017 | 3305 | 0.070 |
Why?
|
Receptors, CXCR3 | 1 | 2006 | 237 | 0.070 |
Why?
|
Registries | 2 | 2020 | 8089 | 0.070 |
Why?
|
Inflammation Mediators | 1 | 2014 | 1889 | 0.070 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2699 | 0.070 |
Why?
|
Quality of Life | 2 | 2023 | 12804 | 0.060 |
Why?
|
Contrast Media | 2 | 2018 | 5300 | 0.060 |
Why?
|
Aspirin | 1 | 2017 | 3282 | 0.060 |
Why?
|
Personal Autonomy | 1 | 2007 | 298 | 0.060 |
Why?
|
Electrocardiography | 1 | 2018 | 6442 | 0.060 |
Why?
|
Animals | 5 | 2020 | 168757 | 0.060 |
Why?
|
Perfusion | 2 | 2023 | 1360 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5391 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3610 | 0.060 |
Why?
|
Communication Barriers | 1 | 2007 | 398 | 0.060 |
Why?
|
Linear Models | 1 | 2014 | 5952 | 0.060 |
Why?
|
Retroviridae | 1 | 2006 | 914 | 0.060 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8949 | 0.060 |
Why?
|
Endocarditis, Bacterial | 1 | 2007 | 455 | 0.060 |
Why?
|
Aortic Valve Insufficiency | 1 | 2007 | 579 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2015 | 2538 | 0.050 |
Why?
|
Heart Defects, Congenital | 1 | 2019 | 4584 | 0.050 |
Why?
|
United States | 7 | 2023 | 69872 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3158 | 0.050 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2006 | 476 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4371 | 0.050 |
Why?
|
Logistic Models | 2 | 2014 | 13408 | 0.050 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2022 | 177 | 0.050 |
Why?
|
Imidazolidines | 1 | 2001 | 39 | 0.050 |
Why?
|
Peer Review | 1 | 2023 | 209 | 0.050 |
Why?
|
Cytokines | 2 | 2006 | 7322 | 0.050 |
Why?
|
Cohort Studies | 3 | 2019 | 40561 | 0.050 |
Why?
|
Diphosphates | 1 | 2020 | 88 | 0.050 |
Why?
|
Comorbidity | 1 | 2014 | 10388 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12354 | 0.040 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 378 | 0.040 |
Why?
|
Macrophages | 1 | 2014 | 5655 | 0.040 |
Why?
|
Adult | 8 | 2021 | 214055 | 0.040 |
Why?
|
Prealbumin | 1 | 2020 | 210 | 0.040 |
Why?
|
Boston | 3 | 2019 | 9313 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 5751 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7659 | 0.040 |
Why?
|
Mitral Valve Insufficiency | 1 | 2007 | 1422 | 0.040 |
Why?
|
Program Development | 1 | 2023 | 1316 | 0.040 |
Why?
|
History, 20th Century | 1 | 2004 | 2740 | 0.040 |
Why?
|
Incidence | 1 | 2014 | 20947 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2006 | 5524 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2022 | 1125 | 0.030 |
Why?
|
Imidazoles | 1 | 2001 | 1206 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 53288 | 0.030 |
Why?
|
Diastole | 1 | 2017 | 791 | 0.030 |
Why?
|
Heart Atria | 1 | 2021 | 1357 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 21683 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20822 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2006 | 9734 | 0.030 |
Why?
|
Young Adult | 2 | 2019 | 56430 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2879 | 0.030 |
Why?
|
Neutrophils | 1 | 2006 | 3719 | 0.030 |
Why?
|
Myocardium | 1 | 2006 | 4776 | 0.030 |
Why?
|
Graft Rejection | 1 | 2006 | 4397 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2017 | 770 | 0.030 |
Why?
|
Adolescent | 2 | 2019 | 85781 | 0.030 |
Why?
|
Life Style | 1 | 2023 | 3835 | 0.030 |
Why?
|
Medical Oncology | 1 | 2023 | 2265 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2017 | 2029 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 2031 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2006 | 10481 | 0.020 |
Why?
|
Time Factors | 3 | 2017 | 40075 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1107 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2017 | 2170 | 0.020 |
Why?
|
Communication | 1 | 2023 | 3749 | 0.020 |
Why?
|
Pericardium | 1 | 2014 | 667 | 0.020 |
Why?
|
Phenotype | 1 | 2006 | 16365 | 0.020 |
Why?
|
Clinical Competence | 1 | 2004 | 4687 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2297 | 0.020 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2009 | 205 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2018 | 2268 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9146 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 12072 | 0.020 |
Why?
|
Probability | 1 | 2014 | 2505 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2006 | 10180 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3584 | 0.020 |
Why?
|
Calcium | 1 | 2020 | 5756 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2925 | 0.020 |
Why?
|
Peripheral Vascular Diseases | 1 | 2009 | 550 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3527 | 0.020 |
Why?
|
Hospitals | 1 | 2019 | 3952 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.020 |
Why?
|
Echocardiography | 1 | 2017 | 5102 | 0.020 |
Why?
|
Biopsy | 1 | 2016 | 6756 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2017 | 12026 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2009 | 3508 | 0.010 |
Why?
|
Kidney | 1 | 2017 | 7186 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9687 | 0.010 |
Why?
|
Allosteric Regulation | 1 | 2001 | 408 | 0.010 |
Why?
|
Hospitalization | 1 | 2019 | 10262 | 0.010 |
Why?
|
Mice | 1 | 2006 | 81183 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2001 | 1155 | 0.010 |
Why?
|
Child, Preschool | 1 | 2019 | 41006 | 0.010 |
Why?
|
Epitopes | 1 | 2001 | 2571 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2001 | 3144 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2001 | 6314 | 0.010 |
Why?
|
Protein Conformation | 1 | 2001 | 4011 | 0.010 |
Why?
|
Up-Regulation | 1 | 2001 | 4217 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 21746 | 0.010 |
Why?
|
Child | 1 | 2019 | 77709 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2001 | 3768 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2001 | 10943 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2001 | 4149 | 0.000 |
Why?
|